We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Read MoreHide Full Article
Shares of Trevena (TRVN - Free Report) gained 2.19% on Mar 8, after the company announced the initiation of a new study that complements the ongoing phase I proof-of-concept study to evaluate TRV045 — a novel sphingosine-1- phosphate receptor modulator selective for the S1P receptor subtype 1.
Trevena's shares have dropped 91.1% in the past year compared with the industry's 3.8% decline.
Image Source: Zacks Investment Research
This is the second proof-of-concept study that will evaluate TRV045 as a potential treatment of epilepsy. The study will assess how TRV045 affects the ability of brain cells to conduct electrical stimulation with the use of Transcranial Magnetic Stimulation (TMS). The effects of TMS will be explored using electromyography (EMG) and electroencephalography (EEG) to measure the potential effect of TRV045 on brain function.
The study is a randomized, double-blind, placebo-controlled, two-way cross-over and a multiple-dose. Twenty-four healthy male volunteers will be enrolled for the same. Each subject will receive one of two treatment sequences in random order of TRV045 250 mg followed by placebo or placebo followed by TRV045 250 mg, with each treatment sequence given once daily for four consecutive days.
Then, the EMG and EEG outcomes in response to TMS will be explored after each treatment sequence's first and last doses. The study is expected to complete enrollment by mid-2023.
The study will provide further insight into TRV045 target engagement and mechanism of action for potentially treating epilepsy and other CNS disorders. The company anticipates reporting top-line data from the study, later this year.
Trevena also has one approved product in the United States, Olinvyk (oliceridine) injection, for the management of acute pain in adults. The company’s other pipelines include TRV250, for the acute treatment of migraine, and TRV734, for the maintenance treatment of opioid use disorder.
Kala Pharmaceuticals’ loss per share estimates have narrowed from $19.67 to $16.25 for 2023, in the past 60 days. The stock has plunged 61.4% in the past year.
KALA’s earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
CRISPR Therapeutics' loss per share estimates for 2023 have narrowed from $8.21 to $7.39, in the past 60 days.
CRSP's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 3.19%. The stock has declined 23.2% in the past year.
Allogene Therapeutics’ loss per share estimates have narrowed from $2.84 to $2.57 for 2023, and from $2.79 to $2.49 for 2024, in the past 60 days. The stock has plunged 31.3% in the past year.
ALLO’s earnings beat estimates in all the last four quarters, the average surprise being 8.33%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Shares of Trevena (TRVN - Free Report) gained 2.19% on Mar 8, after the company announced the initiation of a new study that complements the ongoing phase I proof-of-concept study to evaluate TRV045 — a novel sphingosine-1- phosphate receptor modulator selective for the S1P receptor subtype 1.
Trevena's shares have dropped 91.1% in the past year compared with the industry's 3.8% decline.
Image Source: Zacks Investment Research
This is the second proof-of-concept study that will evaluate TRV045 as a potential treatment of epilepsy. The study will assess how TRV045 affects the ability of brain cells to conduct electrical stimulation with the use of Transcranial Magnetic Stimulation (TMS). The effects of TMS will be explored using electromyography (EMG) and electroencephalography (EEG) to measure the potential effect of TRV045 on brain function.
The study is a randomized, double-blind, placebo-controlled, two-way cross-over and a multiple-dose. Twenty-four healthy male volunteers will be enrolled for the same. Each subject will receive one of two treatment sequences in random order of TRV045 250 mg followed by placebo or placebo followed by TRV045 250 mg, with each treatment sequence given once daily for four consecutive days.
Then, the EMG and EEG outcomes in response to TMS will be explored after each treatment sequence's first and last doses. The study is expected to complete enrollment by mid-2023.
The study will provide further insight into TRV045 target engagement and mechanism of action for potentially treating epilepsy and other CNS disorders. The company anticipates reporting top-line data from the study, later this year.
Trevena also has one approved product in the United States, Olinvyk (oliceridine) injection, for the management of acute pain in adults. The company’s other pipelines include TRV250, for the acute treatment of migraine, and TRV734, for the maintenance treatment of opioid use disorder.
Trevena, Inc. Price and Consensus
Trevena, Inc. price-consensus-chart | Trevena, Inc. Quote
Zacks Rank & Stocks to Consider
Trevena currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include Kala Pharmaceuticals (KALA - Free Report) and CRISPR Therapeutics (CRSP - Free Report) both holding a Zacks Rank #2 (Buy), and Allogene Therapeutics (ALLO - Free Report) holding a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Kala Pharmaceuticals’ loss per share estimates have narrowed from $19.67 to $16.25 for 2023, in the past 60 days. The stock has plunged 61.4% in the past year.
KALA’s earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
CRISPR Therapeutics' loss per share estimates for 2023 have narrowed from $8.21 to $7.39, in the past 60 days.
CRSP's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 3.19%. The stock has declined 23.2% in the past year.
Allogene Therapeutics’ loss per share estimates have narrowed from $2.84 to $2.57 for 2023, and from $2.79 to $2.49 for 2024, in the past 60 days. The stock has plunged 31.3% in the past year.
ALLO’s earnings beat estimates in all the last four quarters, the average surprise being 8.33%.